| Identification | Back Directory | [Name]
2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoic acid | [CAS]
476436-68-7 | [Synonyms]
LY9818
LY-9818
LY 9818
LY519818
LY-519818
LY 519818
naveglitazar
2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoic acid
Benzenepropanoic acid, α-methoxy-4-[3-(4-phenoxyphenoxy)propoxy]-, (αS)- | [Molecular Formula]
C25H26O6 | [MOL File]
476436-68-7.mol | [Molecular Weight]
422.47 |
| Hazard Information | Back Directory | [Uses]
Treatment of Type II diabetes and associated cardiovascular indications. | [Definition]
ChEBI: Naveglitazar is an aromatic ether. | [in vivo]
[14C]Naveglitazar is quickly absorbed and moderately metabolized before elimination. After oral administration, 47, 31, and 62% of the radioactivity, as assessed by AUC values, are circulating as metabolites in mice, rats, and monkeys, respectively. Half-lives for Naveglitazar and radioactivity are similar within each species; however, monkeys have substantially longer half-lives in comparison to mice and rats. Naveglitazar and radioactivity are slowly cleared from the system circulation in all species evaluated[1]. |
|
|